RankAlpha logo
Back to Rankings

IART

Integra LifeSciencesB
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-20
View Chart
Current thesis
The bull case after earnings is straightforward: Q1 beat prior-year levels, margins improved, full-year adjusted EPS guidance moved higher, and Tissue Reconstruction showed better momentum helped by Integra Skin, PriMatrix, and Durepair. If the end-June SurgiMend production target is met, investors may start paying for a cleaner 2026-2027 recovery path.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -4.4.
What can break
Net debt of about $1.6 billion and leverage of 4.1x reduce room for operational misses.
Momentum
86
Value
57
Sentiment
38
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.50 · Bull $17.00 · Bear $10.50
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $18.63
Why
Momentum86 · Δ7d -4.4
Value57 · Δ7d -0.1
Sentiment38 · Δ7d -4.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
86
26% active weight
Current posture
7d trendImproving
Δ7d
-4.4
Δ21d
-12.8
Value
57
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.6
Sentiment
38
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.0
Δ21d
-3.4
Why this grade

Composite grade B. Momentum 86.5 / Value 57.2 / Sentiment 38.3

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.47B
Beta
1.04
Shares Out
77.8M
P/E (TTM) · Derived
-2.8
P/S (TTM)
0.60
P/FCF (TTM)
65.17
Rev YoY
+2.4%
EPS YoY
-81.9%
Gross Margin
+55.1%
Op Margin
-29.3%
Net Debt
$1.77B
Current Ratio
3.38
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology